Inflarx NV logo

IFRX - Inflarx NV News Story

$3.47 0.1  1.8%

Last Trade - 11/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £104.4m
Enterprise Value £35.2m
Revenue £n/a
Position in Universe 4792nd / 6852

InflaRx to Present at Upcoming Investor Conferences

Wed 3rd March, 2021 12:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210303:nGNX2FbWXH&default-theme=true


InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company
developing anti-inflammatory therapeutics by targeting the complement system,
today announced that management will present at two upcoming virtual investor
conferences.

H.C. Wainwright Global Life Sciences Conference
March 9-10, 2021
An on-demand corporate presentation from Prof. Niels C. Riedemann, Chief
Executive Officer and Founder of InflaRx, will be available starting at 7:00
am EST (1:00 pm CET) on March 9, 2021. A webcast
(https://www.globenewswire.com/Tracker?data=-ZqAO5EcUKxHIYlAKrfMxin7LhvS0K2dCNbTWevJUAG1q-uwivwWe5TahjkPaeRbbqv2_4sDWp4MEOZA36_UO_Top86j1xa-3oLTnQCKlIc-Lwu7jK0x0HRUTDunLedF)
of the event will be accessible on the InflaRx website in the Investors
section under Events & Presentations.

Oppenheimer 31(st) Annual Healthcare Conference
Tuesday, March 16, 2021 at 8:00 am EST (1:00 pm CET)
A live webcasted
(https://www.globenewswire.com/Tracker?data=4HaP9QXGuJWskrzxLbtqr7pOXr3MzU0cqpVqMjUXzyctsU2rBPSHn6RC149-HKW0HO4Q7fBxkAhY4Nme6EGEiw2LuRAeHEJX8GN_nCcI_f9Q0KqdlsiC4QjIz5UefQH3_fQVOMW7K6n-AuAW_PGofg==) corporate
presentation from Prof. Riedemann will be available on the InflaRx website in
the Investors section under Events & Presentations. A replay of the
presentation will be accessible on InflaRx’s website following the live
event.

About InflaRx N.V.: 
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused
on applying its proprietary anti-C5a technology to discover and develop
first-in-class, potent and specific inhibitors of C5a. Complement C5a is a
powerful inflammatory mediator involved in the progression of a wide variety
of autoimmune and other inflammatory diseases. InflaRx was founded in 2007,
and the group has offices and subsidiaries in Jena and Munich, Germany, as
well as Ann Arbor, MI, USA. For further information please visit
www.inflarx.com.

Contacts:

InflaRx N.V.
Jordan Zwick – Chief Strategy Officer
Email: IR@inflarx.de
Tel: +1 917-338-6523

MC Services AG
Katja Arnold, Laurie Doyle, Andreas Jungfer
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
US: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other
than statements of historical fact are forward-looking statements, which are
often indicated by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “believe,” “estimate,” “predict,”
“potential” or “continue” and similar expressions. Forward-looking
statements appear in a number of places throughout this release and may
include statements regarding our intentions, beliefs, projections, outlook,
analyses and current expectations concerning, among other things, our ongoing
and planned preclinical development and clinical trials; the impact of the
COVID-19 pandemic on the Company; the timing and our ability to commence and
conduct clinical trials; potential results from current or potential future
collaborations; our ability to make regulatory filings, obtain positive
guidance from regulators, and obtain and maintain regulatory approvals for our
product candidates; our intellectual property position; our ability to develop
commercial functions; expectations regarding clinical trial data; our results
of operations, cash needs, financial condition, liquidity, prospects, future
transactions, growth and strategies; the industry in which we operate; the
trends that may affect the industry or us and the risks uncertainties and
other factors described under the heading “Risk Factors” in InflaRx’s
periodic filings with the Securities and Exchange Commission. These statements
speak only as of the date of this press release and involve known and unknown
risks, uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the
forward-looking statements. Given these risks, uncertainties and other
factors, you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these forward-looking
statements, even if new information becomes available in the future, except as
required by law.

(https://www.globenewswire.com/NewsRoom/AttachmentNg/b865827c-d3ff-479b-90ea-5284ef1a1a8c)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.